Search Results - "Martin, Eric S"

Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism by Ying, Haoqiang, Kimmelman, Alec C., Lyssiotis, Costas A., Hua, Sujun, Chu, Gerald C., Fletcher-Sananikone, Eliot, Locasale, Jason W., Son, Jaekyoung, Zhang, Hailei, Coloff, Jonathan L., Yan, Haiyan, Wang, Wei, Chen, Shujuan, Viale, Andrea, Zheng, Hongwu, Paik, Ji-hye, Lim, Carol, Guimaraes, Alexander R., Martin, Eric S., Chang, Jeffery, Hezel, Aram F., Perry, Samuel R., Hu, Jian, Gan, Boyi, Xiao, Yonghong, Asara, John M., Weissleder, Ralph, Wang, Y. Alan, Chin, Lynda, Cantley, Lewis C., DePinho, Ronald A.

“…Tumor maintenance relies on continued activity of driver oncogenes, although their rate-limiting role is highly context dependent. Oncogenic Kras mutation is…”
Get full text

A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype by WILSON, Wyndham H, JUNG, Sin-Ho, JONES, Dan, DUNLEAVY, Kieron, CANELLOS, George, ZELENETZ, Andrew D, CHESON, Bruce D, HSI, Eric D, PORCU, Pierluigi, HURD, David, JOHNSON, Jeffrey, ERIC MARTIN, S, CZUCZMAN, Myron, LAI, Raymond, SAID, Jonathan, CHADBURN, Amy

“…A phase II trial of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (DA-EPOCH-R) from the National Cancer…”
Get full text

The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer by Roper, Jatin, Richardson, Michael P, Wang, Wei Vivian, Richard, Larissa Georgeon, Chen, Wei, Coffee, Erin M, Sinnamon, Mark J, Lee, Lydia, Chen, Peng-Chieh, Bronson, Roderick T, Martin, Eric S, Hung, Kenneth E

“…To examine the in vitro and in vivo efficacy of the dual PI3K/mTOR inhibitor NVP-BEZ235 in treatment of PIK3CA wild-type colorectal cancer (CRC). PIK3CA mutant…”
Get full text

A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701 by Grant, Barbara W., Jung, Sin‐Ho, Johnson, Jeffrey L., Kostakoglu, Lale, Hsi, Eric, Byrd, John C., Jones, Jeffrey, Leonard, John P., Martin, S. Eric, Cheson, Bruce D.

“…BACKGROUND Rituximab combined with chemotherapy has improved the survival of previously untreated patients with follicular lymphoma (FL). Nevertheless, many…”
Get full text

High-Resolution Genomic Profiles of Human Lung Cancer by Tonon, Giovanni, Wong, Kwok-Kin, Maulik, Gautam, Brennan, Cameron, Feng, Bin, Zhang, Yunyu, Khatry, Deepak B., Protopopov, Alexei, You, Mingjian James, Aguirre, Andrew J., Martin, Eric S., Yang, Zhaohui, Ji, Hongbin, Chin, Lynda, DePinho, Ronald A., Cavenee, Webster K.

“…Lung cancer is the leading cause of cancer mortality worldwide, yet there exists a limited view of the genetic lesions driving this disease. In this study, an…”
Get full text

A Genetic Screen for Candidate Tumor Suppressors Identifies REST by Westbrook, Thomas F., Martin, Eric S., Schlabach, Michael R., Leng, Yumei, Liang, Anthony C., Feng, Bin, Zhao, Jean J., Roberts, Thomas M., Mandel, Gail, Hannon, Gregory J., DePinho, Ronald A., Chin, Lynda, Elledge, Stephen J.

“…Tumorigenesis is a multistep process characterized by a myriad of genetic and epigenetic alterations. Identifying the causal perturbations that confer…”
Get full text

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer by Roper, Jatin, Sinnamon, Mark J, Coffee, Erin M, Belmont, Peter, Keung, Lily, Georgeon-Richard, Larissa, Wang, Wei Vivian, Faber, Anthony C, Yun, Jihye, Yilmaz, Ömer H, Bronson, Roderick T, Martin, Eric S, Tsichlis, Philip N, Hung, Kenneth E

“…Abstract PI3K inhibition in combination with other agents has not been studied in the context of PIK3CA wild-type, KRAS mutant cancer. In a screen of…”
Get full text

Human Chronic Lymphocytic Leukemia Modeled in Mouse by Targeted TCL1 Expression by Bichi, Roberta, Shinton, Susan A., Martin, Eric S., Koval, Anatoliy, Calin, George A., Cesari, Rossano, Russo, Giandomenico, Hardy, Richard R., Croce, Carlo M.

“…The TCL1 gene at 14q32.1 is involved in chromosomal translocations and inversions in mature T cell leukemias. These leukemias are classified either as T…”
Get full text

Parkin, a Gene Implicated in Autosomal Recessive Juvenile Parkinsonism, Is a Candidate Tumor Suppressor Gene on Chromosome 6q25-q27 by Cesari, Rossano, Martin, Eric S., Calin, George A., Pentimalli, Francesca, Bichi, Roberta, McAdams, Holly, Trapasso, Francesco, Drusco, Alessandra, Shimizu, Masayoshi, Masciullo, Valeria, d'Andrilli, Giuseppina, Scambia, Giovanni, Picchio, Maria Cristina, Alder, Hansjuerg, Godwin, Andrew K., Croce, Carlo M.

“…In an effort to identify tumor suppressor gene(s) associated with the frequent loss of heterozygosity observed on chromosome 6q25-q27, we constructed a contig…”
Get full text

Spotlight on International Quality: COVID-19 and Its Impact on Quality Improvement in Cancer Care by Blayney, Douglas W., Bariani, Giovanni, Das, Devika, Dawood, Shaheenah, Gnant, Michael, De Guzman, Roselle, Martin, S. Eric, O'Mahony, Deirdre, Roach, Alex, Ruff, Paul, Sampaio, Carlos, Sanchez, Jose Angel, Vanderpuye, Verna, Kamal, Arif, Hendricks, Carolyn

“…This report from ASCO's International Quality Steering Group summarizes early learnings on how the COVID-19 pandemic and its stresses have disproportionately…”
Get full text

Common and Distinct Genomic Events in Sporadic Colorectal Cancer and Diverse Cancer Types by MARTIN, Eric S, TONON, Giovanni, KUCHERLAPATI, Raju, BAILEY, Gerald, REDSTON, Mark, CHIN, Lynda, DEPINHO, Ronald A, SINHA, Raktim, YONGHONG XIAO, BIN FENG, KIMMELMAN, Alec C, PROTOPOPOV, Alexei, IVANOVA, Elena, BRENNAN, Cameron, MONTGOMERY, Kate

“…Colorectal cancer (CRC) is a major cause of cancer morbidity and mortality, and elucidation of its underlying genetics has advanced diagnostic screening, early…”
Get full text

International Perspective on the Pursuit of Quality in Cancer Care: Global Application of QOPI and QOPI Certification by Blayney, Douglas W, Albdelhafeez, Nafisa, Jazieh, Abdul Rahman, Pinto, Carlos Frederico, Udrea, Adrian, Roach, Alex, Das, Devika, Grubbs, Stephen, Hamm, John, Jahanzeb, Mohammad, Kamal, Arif H, Kelly, Ronan J, Martin, S Eric, O'Mahony, Deirdre, Birch, Walter, Bowman, Ronda, Crist, Stéphanie T S, Evers, Amy, Gilmore, Terry, Klein, Meredith, Siegel, Robert

Get full text

The BCSC-1 Locus at Chromosome 11q23-q24 Is a Candidate Tumor Suppressor Gene by Martin, Eric S., Cesari, Rossano, Pentimalli, Francesca, Yoder, Kristine, Fishel, Richard, Himelstein, Andrew L., Martin, S. Eric, Godwin, Andrew K., Negrini, Massimo, Croce, Carlo M.

“…Frequent allelic loss at human chromosome 11q23-q24 occurs in a wide variety of cancers, suggesting that this region may harbor a tumor suppressor gene. By…”
Get full text

Identification of a HMGA2-EFCAB6 gene rearrangement following next-generation sequencing in a patient with a t(12;22)(q14.3;q13.2) and JAK2V617F -positive myeloproliferative neoplasm by Martin, S. Eric, Sausen, Mark, Joseph, Abraham, Kingham, Brewster F, Martin, Eric S

“…Myeloproliferative neoplasms (MPNs) result from genetically altered hematopoietic stem cells that retain the capacity for multilineage differentiation. The…”
Get full text

Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer by COFFEE, Erin M, FABER, Anthony C, BRONSON, Roderick T, TEJPAR, Sabine, XAVIER, Ramnik J, ENGELMAN, Jeffrey A, MARTIN, Eric S, HUNG, Kenneth E, ROPER, Jatin, SINNAMON, Mark J, GOEL, Gautam, KEUNG, Lily, WEI VIVIAN WANG, VECCHIONE, Loredana, DE VRIENDT, Veerle, WEINSTEIN, Barbara J

“…Abstract Purpose: BRAFV600E mutations are associated with poor clinical prognosis in colorectal cancer (CRC). Although selective BRAF inhibitors are effective…”
Get full text

Telomere dysfunction induces metabolic and mitochondrial compromise by Sahin, Ergün, Colla, Simona, Liesa, Marc, Moslehi, Javid, Müller, Florian L., Guo, Mira, Cooper, Marcus, Kotton, Darrell, Fabian, Attila J., Walkey, Carl, Maser, Richard S., Tonon, Giovanni, Foerster, Friedrich, Xiong, Robert, Wang, Y. Alan, Shukla, Sachet A., Jaskelioff, Mariela, Martin, Eric S., Heffernan, Timothy P., Protopopov, Alexei, Ivanova, Elena, Mahoney, John E., Kost-Alimova, Maria, Perry, Samuel R., Bronson, Roderick, Liao, Ronglih, Mulligan, Richard, Shirihai, Orian S., Chin, Lynda, DePinho, Ronald A.

“…Telomere dysfunction activates p53-mediated cellular growth arrest, senescence and apoptosis to drive progressive atrophy and functional decline in…”
Get full text

Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402 by Kahl, Brad S, Hong, Fangxin, Williams, Michael E, Gascoyne, Randy D, Wagner, Lynne I, Krauss, John C, Habermann, Thomas M, Swinnen, Lode J, Schuster, Stephen J, Peterson, Christopher G, Sborov, Mark D, Martin, S Eric, Weiss, Matthias, Ehmann, W Christopher, Horning, Sandra J

“…In low-tumor burden follicular lymphoma (FL), maintenance rituximab (MR) has been shown to improve progression-free survival when compared with observation. It…”
Get full text

Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease by Belmont, Peter J, Budinska, Eva, Jiang, Ping, Sinnamon, Mark J, Coffee, Erin, Roper, Jatin, Xie, Tao, Rejto, Paul A, Derkits, Sahra, Sansom, Owen J, Delorenzi, Mauro, Tejpar, Sabine, Hung, Kenneth E, Martin, Eric S

“…Effective treatment options for advanced colorectal cancer (CRC) are limited, survival rates are poor and this disease continues to be a leading cause of…”
Get full text

BRCA1 E1644X: a deleterious mutation in an African American individual with early onset breast cancer by Martin, S. Eric, Sausen, Mark, Joseph, Abraham, Biggs, David D, Kingham, Brewster F, Martin, Eric S

“…An African American individual with early onset breast cancer has a unique BRCA1 germline mutation, E1644X, that truncates the protein's carboxy terminal…”
Get full text

Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations by Tyhonas, John S., Arnold, Lee D., Cox, Jason M., Franovic, Aleksandra, Gardiner, Elisabeth, Grandinetti, Kathryn, Kania, Robert, Kanouni, Toufike, Lardy, Matthew, Li, Chun, Martin, Eric S., Miller, Nichol, Mohan, Adithi, Murphy, Eric A., Perez, Michelle, Soroceanu, Liliana, Timple, Noel, Uryu, Sean, Womble, Scott, Kaldor, Stephen W.

“…Fibroblast growth factor receptor (FGFR) alterations are present as oncogenic drivers and bypass mechanisms in many forms of cancer. These alterations can…”
Get full text